Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Celularity, Inc. (CELU : NSDQ)
 
 • Company Description   
Celularity Inc. is a clinical stage biotechnology company. It involved in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR and mesenchymal-like adherent stromal cells targeting indications across cancer, infectious and degenerative diseases. Celularity Inc., formerly known as GX Acquisition Corp., is based in NEW YORK.

Number of Employees: 123

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.32 Daily Weekly Monthly
20 Day Moving Average: 130,336 shares
Shares Outstanding: 26.69 (millions)
Market Capitalization: $61.92 (millions)
Beta: 0.81
52 Week High: $5.22
52 Week Low: $1.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -32.95% -34.13%
12 Week 29.61% 17.73%
Year To Date 11.54% 0.02%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
170 PARK AVE
-
FLORHAM PARK,NJ 07932
USA		 ph: 908-768-2170
fax: -		 carlos.ramirez@celularity.com http://www.celularity.com
 
 • General Corporate Information   
Officers
Robert J. Hariri - Chief Executive Officer and Chairman
David C. Beers - Chief Financial Officer
Dean C. Kehler - Director
Diane Parks - Director
Geoffrey Ling - Director

Peer Information
Celularity, Inc. (CORR.)
Celularity, Inc. (RSPI)
Celularity, Inc. (CGXP)
Celularity, Inc. (BGEN)
Celularity, Inc. (GTBP)
Celularity, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 151190204
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/25
Next Expected EPS Date: 12/05/25
Share - Related Items
Shares Outstanding: 26.69
Most Recent Split Date: 2.00 (0.10:1)
Beta: 0.81
Market Capitalization: $61.92 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 12/05/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 1.39
EPS Growth
vs. Year Ago Period: -240.00%
vs. Previous Quarter: -21.43%
Sales Growth
vs. Year Ago Period: -52.64%
vs. Previous Quarter: -49.80%
ROE
06/30/25 - -
03/31/25 - -459.57
12/31/24 - -271.88
ROA
06/30/25 - -57.71
03/31/25 - -42.31
12/31/24 - -42.82
Current Ratio
06/30/25 - 0.25
03/31/25 - 0.38
12/31/24 - 0.38
Quick Ratio
06/30/25 - 0.19
03/31/25 - 0.27
12/31/24 - 0.28
Operating Margin
06/30/25 - -165.22
03/31/25 - -109.16
12/31/24 - -106.77
Net Margin
06/30/25 - -165.22
03/31/25 - -109.16
12/31/24 - -106.77
Pre-Tax Margin
06/30/25 - -165.21
03/31/25 - -109.16
12/31/24 - -106.77
Book Value
06/30/25 - -1.04
03/31/25 - -0.23
12/31/24 - 0.37
Inventory Turnover
06/30/25 - 4.01
03/31/25 - 3.66
12/31/24 - 3.75
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - 4.07
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - 80.26
 

Powered by Zacks Investment Research ©